Novel anti-inflammatory slows progression of MS in mice
When delivered intranasally, the anti-inflammatory drug VX-765 prevented axon demyelination and loss in a murine model of multiple sclerosis (MS).
List view / Grid view
When delivered intranasally, the anti-inflammatory drug VX-765 prevented axon demyelination and loss in a murine model of multiple sclerosis (MS).
Combining 2D and 3D models with live-cell assays allows monitoring of cell responses in real time and provides important insights about compound treatment effects, biological complexity, and physiological relevance of assay results.
Learn how to perform complex analysis of calcium oscillations and assess cellular and mitochondrial toxicity.
Neurological symptoms have been observed in COVID-19 patients. The link between SARS-CoV-2 and the CNS is critical to developing effective treatments
Water immersion objectives are essential for capturing more data at greater depths in 3D structures, such as spheroids and thick tissues.
Evaluating and quantitating nuclear transduction.
Researchers have found that the surface of SARS-CoV-2 can take on at least 10 different structural states when in contact with ACE2.
There has been growing interest in using high-content imaging methods for studying mitochondria.
Explore this virtual tour of the ImageXpress Pico Automated Cell Imaging System from Molecular Devices, including hardware and software.
A new interactive map of the surface of SARS-CoV-2, featuring the Spike, Envelope and Membrane proteins, has been released for researchers to use.
Explore this virtual tour of the ImageXpress Micro Confocal High-Content Imaging System from Molecular Devices, including hardware and software.
24 September 2020 | By PerkinElmer
During this on-demand webinar, two leading researchers will discuss their innovative approaches to developing novel opportunities for immunotherapy treatments.
Helping in the race to identify effective neutralising antibodies against the spike protein of SARS-CoV-2 virus as the COVID-19 global death rate continues to rise.
A pocket in the SARS-CoV-2 Spike protein has been discovered by researchers, who say it could be a drug target for COVID-19.
Many anti-angiogenic drugs have been developed to use in cancer therapy, while pro-angiogenic molecules may hold potential in regenerative applications.